The role of chemokines in the pathogenesis of neurotropic flaviviruses

Immunologic Research

Volumn 54, Issue 1-3, 2012, Pages 121-132

  Bardina, Susana V ^a   Lim, Jean K ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Chemoattractant; Immunopathogenesis; Leukocyte trafficking; Neuroinvasion; Viral encephalitis

Indexed keywords

ANTIVIRUS AGENT; CHEMOATTRACTANT; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 8; RANTES;

CELL MIGRATION; CENTRAL NERVOUS SYSTEM INFECTION; FLAVIVIRUS; FLAVIVIRUS INFECTION; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFLAMMATION; JAPANESE ENCEPHALITIS; JAPANESE ENCEPHALITIS VIRUS; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TICK BORNE ENCEPHALITIS; TICK BORNE ENCEPHALITIS FLAVIVIRUS; VIRUS ENTRY; VIRUS PATHOGENESIS; WEST NILE FEVER; WEST NILE FLAVIVIRUS;

ANIMALS; CHEMOKINES; ENCEPHALITIS, ARBOVIRUS; FLAVIVIRUS; FLAVIVIRUS INFECTIONS; HUMANS; RECEPTORS, CHEMOKINE;

EID: 84867869715     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-012-8333-3     Document Type: Review

References (108)

1. Hayes EB, Gubler DJ. West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med. 2006;57:181-94. doi: 10.1146/annurev.med.57.121304.131418.
2. Lanciotti RS, Roehrig JT, Deubel V, Smith J, Parker M, Steele K, et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science. 1999;286(5448):2333-7.
3. Misra UK, Kalita J. Overview: Japanese encephalitis. Prog Neurobiol. 2010;91(2):108-20. doi: 10.1016/j.pneurobio.2010.01.008.
4. Charrel RN, Attoui H, Butenko AM, Clegg JC, Deubel V, Frolova TV, et al. Tick-borne virus diseases of human interest in Europe. Clin Microbiol Infect. 2004;10(12):1040-55. doi: 10.1111/j.1469-0691.2004.01022.x.
5. Iwamoto M, Jernigan DB, Guasch A, Trepka MJ, Blackmore CG, Hellinger WC, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med. 2003;348(22):2196-203. doi: 10.1056/NEJMoa022987.
6. Balogh Z, Egyed L, Ferenczi E, Ban E, Szomor KN, Takacs M, et al. Experimental infection of goats with tick-borne encephalitis virus and the possibilities to prevent virus transmission by raw goat milk. Intervirology. 2011. doi: 10.1159/000324023.
7. Bakhvalova VN, Potapova OF, Panov VV, Morozova OV. Vertical transmission of tick-borne encephalitis virus between generations of adapted reservoir small rodents. Virus Res. 2009;140(1-2):172-8. doi: 10.1016/j.virusres.2008.12.001.
8. Smithburn KC, Huges TP, Burke AW, Paul JH. A neurotropic virus isolated from the blood of a native Ugandna. Am J Trop Med Hyg. 1940;20:471-92.
9. Weaver SC, Barrett AD. Transmission cycles, host range, evolution and emergence of arboviral disease. Nat Rev Microbiol. 2004;2(10):789-801. doi: 10.1038/nrmicro1006.
10. Debiasi RL. West nile virus neuroinvasive disease. Curr Infect Dis Rep. 2011;13(4):350-9. doi: 10.1007/s11908-011-0193-9.
11. Nash D, Mostashari F, Fine A, Miller J, O'Leary D, Murray K, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med. 2001;344(24):1807-14. doi: 10.1056/nejm200106143442401.
12. Hayes EB, Komar N, Nasci RS, Montgomery SP, O'Leary DR, Campbell GL. Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis. 2005;11(8):1167-73.
13. CDC. West Nile Virus Statistics, Surveillance, and Control Archive. http://www.cdc.gov/ncidod/dvbid/westnile/surv&control.htm. 2011.
14. Sejvar JJ. The long-term outcomes of human West Nile virus infection. Clin Infect Dis. 2007;44(12):1617-24. doi: 10.1086/518281.
15. Brien JD, Uhrlaub JL, Hirsch A, Wiley CA, Nikolich-Zugich J. Key role of T cell defects in age-related vulnerability to West Nile virus. J Exp Med. 2009;206(12):2735-45. doi: 10.1084/jem.20090222.
16. Byrne SN, Halliday GM, Johnston LJ, King NJ. Interleukin-1beta but not tumor necrosis factor is involved in West Nile virus-induced Langerhans cell migration from the skin in C57BL/6 mice. J Invest Dermatol. 2001;117(3):702-9. doi: 10.1046/j.0022-202x.2001.01454.x.
17. Garcia-Tapia D, Hassett DE, Mitchell WJ Jr, Johnson GC, Kleiboeker SB. West Nile virus encephalitis: sequential histopathological and immunological events in a murine model of infection. J Neurovirol. 2007;13(2):130-8. doi: 10.1080/13550280601187185.
18. Johnston LJ, Halliday GM, King NJ. Langerhans cells migrate to local lymph nodes following cutaneous infection with an arbovirus. J Invest Dermatol. 2000;114(3):560-8. doi: 10.1046/j.1523-1747.2000.00904.x.
19. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, Flavell RA. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med. 2004;10(12):1366-73. doi: 10.1038/nm1140.
20. Xiao SY, Guzman H, Zhang H, Travassos da Rosa AP, Tesh RB. West Nile virus infection in the golden hamster (Mesocricetus auratus): a model for West Nile encephalitis. Emerg Infect Dis. 2001;7(4):714-21.
21. Guarner J, Shieh WJ, Hunter S, Paddock CD, Morken T, Campbell GL, et al. Clinicopathologic study and laboratory diagnosis of 23 cases with West Nile virus encephalomyelitis. Hum Pathol. 2004;35(8):983-90.
22. Shieh WJ, Guarner J, Layton M, Fine A, Miller J, Nash D, et al. The role of pathology in an investigation of an outbreak of West Nile encephalitis in New York, 1999. Emerg Infect Dis. 2000;6(4):370-2.
23. Shrestha B, Gottlieb D, Diamond MS. Infection and injury of neurons by West Nile encephalitis virus. J Virol. 2003;77(24):13203-13.
24. Shirato K, Kimura T, Mizutani T, Kariwa H, Takashima I. Different chemokine expression in lethal and non-lethal murine West Nile virus infection. J Med Virol. 2004;74(3):507-13. doi: 10.1002/jmv.20205.
25. Klein RS, Lin E, Zhang B, Luster AD, Tollett J, Samuel MA, et al. Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J Virol. 2005;79(17):11457-66. doi: 10.1128/jvi.79.17.11457-11466. 2005.
26. Glass WG, Lim JK, Cholera R, Pletnev AG, Gao JL, Murphy PM. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med. 2005;202(8):1087-98. doi: 10.1084/jem.20042530.
27. Lim JK, McDermott DH, Lisco A, Foster GA, Krysztof D, Follmann D, et al. CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J Infect Dis. 2010;201(2):178-85. doi: 10.1086/649426.
28. Tobler LH, Cameron MJ, Lanteri MC, Prince HE, Danesh A, Persad D, et al. Interferon and interferon-induced chemokine expression is associated with control of acute viremia in West Nile virus-infected blood donors. J Infect Dis. 2008;198(7):979-83. doi: 10.1086/591466.
29. McCandless EE, Zhang B, Diamond MS, Klein RS. CXCR4 antagonism increases T cell trafficking in the central nervous system and improves survival from West Nile virus encephalitis. Proc Natl Acad Sci USA. 2008;105(32):11270-5. doi: 10.1073/pnas.0800898105.
30. Cheeran MC, Hu S, Sheng WS, Rashid A, Peterson PK, Lokensgard JR. Differential responses of human brain cells to West Nile virus infection. J Neurovirol. 2005;11(6):512-24. doi: 10.1080/13550280500384982.
31. Burton JM, Kern RZ, Halliday W, Mikulis D, Brunton J, Fearon M, et al. Neurological manifestations of West Nile virus infection. Can J Neurol Sci. 2004;31(2):185-93.
32. Sampson BA, Armbrustmacher V. West Nile encephalitis: the neuropathology of four fatalities. Ann NY Acad Sci. 2001;951:172-8.
33. Tyler KL, Pape J, Goody RJ, Corkill M, Kleinschmidt-DeMasters BK. CSF findings in 250 patients with serologically confirmed West Nile virus meningitis and encephalitis. Neurology. 2006;66(3):361-5. doi: 10.1212/01.wnl.0000195890. 70898.1f.
34. Jeha LE, Sila CA, Lederman RJ, Prayson RA, Isada CM, Gordon SM. West Nile virus infection: a new acute paralytic illness. Neurology. 2003;61(1):55-9.
35. Procop GW, Yen-Lieberman B, Prayson RA, Gordon SM. Mollaret-like cells in patients with West Nile virus infection. Emerg Infect Dis. 2004;10(4):753-4.
36. Shrestha B, Diamond MS. Role of CD8+ T cells in control of West Nile virus infection. J Virol. 2004;78(15):8312-21. doi: 10.1128/jvi.78.15.8312-8321. 2004.
37. Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, Frank WA, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med. 2006;203(1):35-40. doi: 10.1084/jem.20051970.
38. Loeb M, Eskandarian S, Rupp M, Fishman N, Gasink L, Patterson J, et al. Genetic variants and susceptibility to neurological complications following West Nile virus infection. J Infect Dis. 2011;204(7):1031-7. doi: 10.1093/infdis/jir493.
39. Bigham AW, Buckingham KJ, Husain S, Emond MJ, Bofferding KM, Gildersleeve H, et al. Host genetic risk factors for West Nile virus infection and disease progression. PLoS ONE. 2011;6(9):e24745. doi: 10.1371/journal.pone.0024745.
40. Lim JK, Louie CY, Glaser C, Jean C, Johnson B, Johnson H, et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis. 2008;197(2):262-5. doi: 10.1086/524691.
41. Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB. Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet. 1997;16(1):100-3. doi: 10.1038/ng0597-100.
42. Orton SL, Stramer SL, Dodd RY. Self-reported symptoms associated with West Nile virus infection in RNA-positive blood donors. Transfusion. 2006;46(2):272-7. doi: 10.1111/j.1537-2995.2006.00710.x.
43. Stramer SL, Fang CT, Foster GA, Wagner AG, Brodsky JP, Dodd RY. West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med. 2005;353(5):451-9. doi: 10.1056/NEJMoa044333.
44. Lim JK, Glass WG, McDermott DH, Murphy PM. CCR5: no longer a good for nothing gene-chemokine control of West Nile virus infection. Trends Immunol. 2006;27(7):308-12. doi: 10.1016/j.it.2006.05.007.
45. Gilliam BL, Riedel DJ, Redfield RR. Clinical use of CCR5 inhibitors in HIV and beyond. J Transl Med. 2011;9(Suppl 1):S9. doi: 10.1186/1479-5876-9-s1- s9.
46. Liu T, Weng Z, Dong X, Hu Y. Recent advances in the development of small-molecule CCR5 inhibitors for HIV. Mini Rev Med Chem. 2010;10(13):1277-92.
47. Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, Mefford M, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science. 2004;306(5695):485-7. doi: 10.1126/science.1099288.
48. McGavern DB, Homann D, Oldstone MB. T cells in the central nervous system: the delicate balance between viral clearance and disease. J Infect Dis. 2002;186(Suppl 2):S145-51. doi: 10.1086/344264.
49. Shrestha B, Samuel MA, Diamond MS. CD8+ T cells require perforin to clear West Nile virus from infected neurons. J Virol. 2006;80(1):119-29. doi: 10.1128/jvi.80.1.119-129.2006.
50. Zhang B, Patel J, Croyle M, Diamond MS, Klein RS. TNF-alpha-dependent regulation of CXCR3 expression modulates neuronal survival during West Nile virus encephalitis. J Neuroimmunol. 2010;224(1-2):28-38. doi: 10.1016/j.jneuroim.2010.05.003.
51. Zhang B, Chan YK, Lu B, Diamond MS, Klein RS. CXCR3 mediates region-specific antiviral T cell trafficking within the central nervous system during West Nile virus encephalitis. J Immunol. 2008;180(4):2641-9.
52. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 1998;393(6685):591-4. doi: 10.1038/31261.
53. Link DC. Neutrophil homeostasis: a new role for stromal cell-derived factor-1. Immunol Res. 2005;32(1-3):169-78. doi: 10.1385/ir:32:1-3:169.
54. Eash KJ, Means JM, White DW, Link DC. CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions. Blood. 2009;113(19):4711-9. doi: 10.1182/blood-2008-09-177287.
55. Capoccia BJ, Shepherd RM, Link DC. G-CSF and AMD3100 mobilize monocytes into the blood that stimulate angiogenesis in vivo through a paracrine mechanism. Blood. 2006;108(7):2438-45. doi: 10.1182/blood-2006-04-013755.
56. McDermott DH, Liu Q, Ulrick J, Kwatemaa N, Anaya-O'Brien S, Penzak SR, et al. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood. 2011;118(18):4957-62. doi: 10.1182/blood-2011-07-368084.
57. Getts DR, Terry RL, Getts MT, Muller M, Rana S, Shrestha B, et al. Ly6c+ inflammatory monocytes are microglial precursors recruited in a pathogenic manner in West Nile virus encephalitis. J Exp Med. 2008;205(10):2319-37. doi: 10.1084/jem.20080421.
58. Ben-Nathan D, Huitinga I, Lustig S, van Rooijen N, Kobiler D. West Nile virus neuroinvasion and encephalitis induced by macrophage depletion in mice. Arch Virol. 1996;141(3-4):459-69.
59. Lim JK, Obara CJ, Rivollier A, Pletnev AG, Kelsall BL, Murphy PM. Chemokine receptor Ccr2 is critical for monocyte accumulation and survival in West Nile virus encephalitis. J Immunol. 2011;186(1):471-8. doi: 10.4049/jimmunol.1003003.
60. Rawal A, Gavin PJ, Sturgis CD. Cerebrospinal fluid cytology in seasonal epidemic West Nile virus meningo-encephalitis. Diagn Cytopathol. 2006;34(2):127-9. doi: 10.1002/dc.20410.
61. Brehin AC, Mouries J, Frenkiel MP, Dadaglio G, Despres P, Lafon M, et al. Dynamics of immune cell recruitment during West Nile encephalitis and identification of a new CD19+ B220-BST-2+ leukocyte population. J Immunol. 2008;180(10):6760-7.
62. Bai F, Kong KF, Dai J, Qian F, Zhang L, Brown CR, et al. A paradoxical role for neutrophils in the pathogenesis of West Nile virus. J Infect Dis. 2010;202(12):1804-12. doi: 10.1086/657416.
63. Kish DD, Li X, Fairchild RL. CD8 T cells producing IL-17 and IFN-gamma initiate the innate immune response required for responses to antigen skin challenge. J Immunol. 2009;182(10):5949-59. doi: 10.4049/jimmunol.0802830.
64. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, et al. Estimated global incidence of Japanese encephalitis: a systemic review. Bull World Health Organ. 2011;89(10):766-74A-74E. doi: 10.2471/blt.10.085233.
65. Halstead SB, Grosz CR. Subclinical Japanese encephalitis. I. Infection of Americans with limited residence in Korea. Am J Hyg. 1962;75:190-201.
66. Huang CH. Studies of Japanese encephalitis in China. Adv Virus Res. 1982;27:71-101.
67. Hammon WM, Sather GE, Mc CH. Serologic survey of Japanese B encephalitis virus infection in birds in Japan. Am J Hyg. 1958;67(1):118-33.
68. Cross JH, Lien JC, Huang WC, Lien SC, Chiu SF. Japanese encephalitis virus surveillance in Taiwan. II. Isolations from mosquitoes and bats in Taipei area 1969-1970. Taiwan Yi Xue Hui Za Zhi. 1971;70(12):681-6.
69. Rosen L. The natural history of Japanese encephalitis virus. Annu Rev Microbiol. 1986;40:395-414. doi: 10.1146/annurev.mi.40.100186.002143.
70. Yasui K. Neuropathogenesis of Japanese encephalitis virus. J Neurovirol. 2002;8(Suppl 2):112-4. doi: 10.1080/13550280290168019.
71. Johnson RT, Burke DS, Elwell M, Leake CJ, Nisalak A, Hoke CH, et al. Japanese encephalitis: immunocytochemical studies of viral antigen and inflammatory cells in fatal cases. Ann Neurol. 1985;18(5):567-73. doi: 10.1002/ana.410180510.
72. Johnson RT, Intralawan P, Puapanwatton S. Japanese encephalitis: identification of inflammatory cells in cerebrospinal fluid. Ann Neurol. 1986;20(6):691-5. doi: 10.1002/ana.410200607.
73. Ruzek D, Salat J, Palus M, Gritsun TS, Gould EA, Dykova I, et al. CD8+ T-cells mediate immunopathology in tick-borne encephalitis. Virology. 2009;384(1):1-6. doi: 10.1016/j.virol.2008.11.023.
74. Fujii Y, Kitaura K, Nakamichi K, Takasaki T, Suzuki R, Kurane I. Accumulation of T-cells with selected T-cell receptors in the brains of Japanese encephalitis virus-infected mice. Jpn J Infect Dis. 2008;61(1):40-8.
75. Yang Y, Ye J, Yang X, Jiang R, Chen H, Cao S. Japanese encephalitis virus infection induces changes of mRNA profile of mouse spleen and brain. Virol J. 2011;8:80. doi: 10.1186/1743-422x-8-80.
76. Bhowmick S, Duseja R, Das S, Appaiahgiri MB, Vrati S, Basu A. Induction of IP-10 (CXCL10) in astrocytes following Japanese encephalitis. Neurosci Lett. 2007;414(1):45-50. doi: 10.1016/j.neulet.2006.11.070.
77. Gupta N, Santhosh SR, Babu JP, Parida MM, Rao PV. Chemokine profiling of Japanese encephalitis virus-infected mouse neuroblastoma cells by microarray and real-time RT-PCR: implication in neuropathogenesis. Virus Res. 2010;147(1):107-12. doi: 10.1016/j.virusres.2009.10.018.
78. Mathur A, Bharadwaj M, Kulshreshtha R, Rawat S, Jain A, Chaturvedi UC. Immunopathological study of spleen during Japanese encephalitis virus infection in mice. Br J Exp Pathol. 1988;69(3):423-32.
79. Chung CC, Lee SS, Chen YS, Tsai HC, Wann SR, Kao CH, et al. Acute flaccid paralysis as an unusual presenting symptom of Japanese encephalitis: a case report and review of the literature. Infection. 2007;35(1):30-2. doi: 10.1007/s15010-007-6038-7.
80. Chaturvedi UC, Mathur A, Tandon P, Natu SM, Rajvanshi S, Tandon HO. Variable effect on peripheral blood leucocytes during JE virus infection of man. Clin Exp Immunol. 1979;38(3):492-8.
81. Mathur A, Khanna N, Chaturvedi UC. Breakdown of blood-brain barrier by virus-induced cytokine during Japanese encephalitis virus infection. Int J Exp Pathol. 1992;73(5):603-11.
82. Singh A, Kulshreshtha R, Mathur A. Secretion of the chemokine interleukin-8 during Japanese encephalitis virus infection. J Med Microbiol. 2000;49(7):607-12.
83. Winter PM, Dung NM, Loan HT, Kneen R, Wills B, le Thu T, et al. Proinflammatory cytokines and chemokines in humans with Japanese encephalitis. J Infect Dis. 2004;190(9):1618-26. doi: 10.1086/423328.
84. Chen CJ, Chen JH, Chen SY, Liao SL, Raung SL. Upregulation of RANTES gene expression in neuroglia by Japanese encephalitis virus infection. J Virol. 2004;78(22):12107-19. doi: 10.1128/jvi.78.22.12107-12119.2004.
85. Gupta N, Rao PV. Transcriptomic profile of host response in Japanese encephalitis virus infection. Virol J. 2011;8:92. doi: 10.1186/1743-422x-8-92.
86. Gritsun TS, Lashkevich VA, Gould EA. Tick-borne encephalitis. Antivir Res. 2003;57(1-2):129-46.
87. Csango PA, Blakstad E, Kirtz GC, Pedersen JE, Czettel B. Tick-borne encephalitis in southern Norway. Emerg Infect Dis. 2004;10(3):533-4.
88. Mansfield KL, Johnson N, Phipps LP, Stephenson JR, Fooks AR, Solomon T. Tick-borne encephalitis virusa review of an emerging zoonosis. J Gen Virol. 2009;90(Pt 8):1781-94. doi: 10.1099/vir.0.011437-0.
89. Suss J. Tick-borne encephalitis in Europe and beyondthe epidemiological situation as of 2007. Euro Surveill. 2008;13(26):1-8.
90. Gritsun TS, Nuttall PA, Gould EA. Tick-borne flaviviruses. Adv Virus Res. 2003;61:317-71.
91. Albrecht P. Pathogenesis of neurotropic arbovirus infections. Curr Top Microbiol Immunol. 1968;43:44-91.
92. Haglund M, Gunther G. Tick-borne encephalitis-pathogenesis, clinical course and long-term follow-up. Vaccine. 2003;21(Suppl 1):S11-8.
93. Labuda M, Austyn JM, Zuffova E, Kozuch O, Fuchsberger N, Lysy J, et al. Importance of localized skin infection in tick-borne encephalitis virus transmission. Virology. 1996;219(2):357-66. doi: 10.1006/viro.1996.0261.
94. Wu ML, Warren DJ, Jones VA. Ticked off: ixodes. Arch Pathol Lab Med. 2000;124(6):925. doi: 10.1043/0003-9985(2000)124<0925:toi>2.0.co;2.
95. Gelpi E, Preusser M, Garzuly F, Holzmann H, Heinz FX, Budka H. Visualization of Central European tick-borne encephalitis infection in fatal human cases. J Neuropathol Exp Neurol. 2005;64(6):506-12.
96. Ruzek D, Salat J, Singh SK, Kopecky J. Breakdown of the blood-brain barrier during tick-borne encephalitis in mice is not dependent on CD8+ T-cells. PLoS ONE. 2011;6(5):e20472. doi: 10.1371/journal.pone.0020472.
97. Hayasaka D, Nagata N, Fujii Y, Hasegawa H, Sata T, Suzuki R, et al. Mortality following peripheral infection with tick-borne encephalitis virus results from a combination of central nervous system pathology, systemic inflammatory and stress responses. Virology. 2009;390(1):139-50. doi: 10.1016/j.virol.2009.04.026.
98. Holub M, Kluckova Z, Beran O, Aster V, Lobovska A. Lymphocyte subset numbers in cerebrospinal fluid: comparison of tick-borne encephalitis and neuroborreliosis. Acta Neurol Scand. 2002;106(5):302-8.
99. Gelpi E, Preusser M, Laggner U, Garzuly F, Holzmann H, Heinz FX, et al. Inflammatory response in human tick-borne encephalitis: analysis of postmortem brain tissue. J Neurovirol. 2006;12(4):322-7. doi: 10.1080/13550280600848746.
100. Zajkowska J, Moniuszko-Malinowska A, Pancewicz SA, Muszynska-Mazur A, Kondrusik M, Grygorczuk S, et al. Evaluation of CXCL10, CXCL11, CXCL12 and CXCL13 chemokines in serum and cerebrospinal fluid in patients with tick borne encephalitis (TBE). Adv Med Sci. 2011;56:1-7. doi: 10.2478/v10039-011-0033-z.
101. Grygorczuk S, Zajkowska J, Swierzbinska R, Pancewicz S, Kondrusik M, Hermanowska-Szpakowicz T. Elevated concentration of the chemokine CCL3 (MIP-1alpha) in cerebrospinal fluid and serum of patients with tick borne encephalitis. Adv Med Sci. 2006;51:340-4.
102. Lepej SZ, Misic-Majerus L, Jeren T, Rode OD, Remenar A, Sporec V, et al. Chemokines CXCL10 and CXCL11 in the cerebrospinal fluid of patients with tick-borne encephalitis. Acta Neurol Scand. 2007;115(2):109-14. doi: 10.1111/j.1600-0404.2006.00726.x.
103. Michalowska-Wender G, Losy J, Kondrusik M, Zajkowska J, Pancewicz S, Grygorczuk S, et al. Evaluation of soluble platelet cell adhesion molecule sPECAM-1 and chemokine MCP-1 (CCL2) concentration in CSF of patients with tick-borne encephalitis]. Pol Merkur Lekarski. 2006;20(115):46-8.
104. Grygorczuk S, Zajkowska J, Swierzbinska R, Pancewicz S, Kondrusik M, Hermanowska-Szpakowicz T. Concentration of the beta-chemokine CCL5 (RANTES) in cerebrospinal fluid in patients with tick-borne encephalitis]. Neurol Neurochir Pol. 2006;40(2):106-11.
105. Kindberg E, Mickiene A, Ax C, Akerlind B, Vene S, Lindquist L, et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis. 2008;197(2):266-9. doi: 10.1086/524709.
106. Diamond MS. Progress on the development of therapeutics against West Nile virus. Antiviral Res. 2009;83(3):214-27. doi: 10.1016/j.antiviral.2009.05.006.
107. Smith CE. A virus resembling Russian spring-summer encephalitis virus from an ixodid tick in Malaya. Nature. 1956;178(4533):581-2.
108. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359(14):1429-41. doi: 10.1056/NEJMoa0803152.